{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:18:33Z","timestamp":1792214313782,"version":"4.4.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We analyzed the characteristics and outcomes of 95 patients with chronic lymphocytic leukemia (CLL) after Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i) failure. To clearly distinguish sensitivity and resistance to the targeted treatment classes, we defined double refractory (DR) CLL when progressive disease occurred during active treatment with a BTKi and a BCL2i, given sequentially or in combination, and double exposed (DE) disease when treatment with either or both of these agents was discontinued due to reasons other than progression. Thirty patients (31.6%) had DR CLL, and 65 (63.2%) had DE CLL. The DR group more frequently had unmutated immunoglobulin gene heavy chain variable (97%), TP53 aberration (73%), and BTK mutations (59%) than the DE group (75%, 46%, and 27%, respectively). The median number of total lines of therapy was 6 for DR and 3 for DE. Nearly all DR patients (97%) required subsequent therapy after developing DR CLL. The most commonly used treatment was noncovalent BTKis (34%), followed by concurrent covalent BTKi and BCL2i (28%) and CD19 chimeric antigen receptor-modified T cells (24%). Treatment for DE CLL was less frequently observed (26%). The median overall survival (OS) was 2.2 years once DR developed, despite the frequent initial responses to noncovalent BTKis or cellular therapy in the cohort. Patients with DE CLL demonstrated favorable survival (median OS not reached) and durable response to subsequent therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016006","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T20:30:46Z","timestamp":1743798646000},"page":"2808-2817","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-087X","authenticated-orcid":false,"given":"James T.","family":"Yoon","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6276-635X","authenticated-orcid":false,"given":"Yinglu","family":"Zhou","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2135-2051","authenticated-orcid":false,"given":"Mariia","family":"Mikhaleva","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Choi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Bessnow","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-5129","authenticated-orcid":false,"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-8584","authenticated-orcid":false,"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-0658","authenticated-orcid":false,"given":"Austin I.","family":"Kim","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-7224","authenticated-orcid":false,"given":"Oreofe O.","family":"Odejide","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-9769","authenticated-orcid":false,"given":"Erin M.","family":"Parry","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-9685","authenticated-orcid":false,"given":"David A.","family":"Qualls","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Ryan","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswin","family":"Sekar","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D.","family":"Soumerai","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, MA"},{"name":"4Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, MA"},{"name":"5Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Tyekucheva","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-287X","authenticated-orcid":false,"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"2025061008265369800_bib1","first-page":"S342","article-title":"CLL-076 final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"24","author":"Burger","year":"2024","journal-title":""},{"issue":"suppl 1","key":"2025061008265369800_bib2","article-title":"Long-term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study","volume":"142","author":"Itsara","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025061008265369800_bib3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"19","key":"2025061008265369800_bib4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"2025061008265369800_bib5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J Clin Oncol"},{"issue":"13","key":"2025061008265369800_bib6","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2024024510","article-title":"Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2025061008265369800_bib7","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025061008265369800_bib8","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/S2152-2650(24)01258-8","article-title":"CLL-057 outcomes in high-risk subgroups after fixed-duration ibrutinib (Ibr) + venetoclax (Ven) for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study","volume":"24","author":"Wierda","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2025061008265369800_bib9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukemia (GLOW): 4-year follow-up from a multicentre, open-lable, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025061008265369800_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"2025061008265369800_bib11","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam","year":"2021","journal-title":"Haematologica"},{"issue":"18","key":"2025061008265369800_bib12","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2025061008265369800_bib13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"2025061008265369800_bib14","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025061008265369800_bib15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2023022861","article-title":"Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia","volume":"144","author":"Lewis","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2025061008265369800_bib16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"issue":"22","key":"2025061008265369800_bib17","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2025061008265369800_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41375-024-02163-4","article-title":"Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia","volume":"38","author":"Chatzikonstantinou","year":"2024","journal-title":"Leukemia"},{"issue":"25","key":"2025061008265369800_bib19","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2025061008265369800_bib20","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1097\/HS9.0000000000000707","article-title":"Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations","volume":"6","author":"Baliakas","year":"2022","journal-title":"Hemasphere"},{"issue":"4","key":"2025061008265369800_bib21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/bloodadvances.2023011574","article-title":"Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL","volume":"8","author":"Ahn","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2025061008265369800_bib22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2025061008265369800_bib23","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025061008265369800_bib24","article-title":"Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: updated analysis from the BRUIN study","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025061008265369800_bib25","article-title":"BRUIN CLL-321: randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"144","author":"Sharman","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025061008265369800_bib26","article-title":"Pirtobrutinib in post-cBTKi CLL\/SLL: \u223c30 months follow-up and subgroup analysis with\/without prior BCL2i from the phase 1\/2 BRUIN study","volume":"142","author":"Woyach","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2025061008265369800_bib27","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/bloodadvances.2022007708","article-title":"Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes","volume":"6","author":"Hyak","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025061008265369800_bib28","article-title":"Lisocabtagene maraleucel (liso-cel) in R\/R CLL\/SLL: 24-month median follow-up of TRANSCEND CLL 004","volume":"142","author":"Siddiqi","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2025061008265369800_bib29","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"2025061008265369800_bib30","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2025061008265369800_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41409-020-01013-y","article-title":"Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study [published correction appears in Bone Marrow Transpl. 2022;57(1):144]","volume":"56","author":"Schetelig","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"17","key":"2025061008265369800_bib32","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025061008265369800_bib34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and safety of the Bruton's tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025061008265369800_bib35","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2808\/2377978\/blooda_adv-2025-016006-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2808\/2377978\/blooda_adv-2025-016006-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:27:02Z","timestamp":1749544022000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/11\/2808\/536517\/Characteristics-and-outcomes-of-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016006","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,10]]},"published":{"date-parts":[[2025,6,2]]}}}